Cerus Corporation, a biomedical products company, is committed to developing and commercializing its proprietary technology, the INTERCEPT Blood System, to enhance blood safety. The company's innovative technology is designed to control biological replication, ultimately reducing blood-borne pathogens in donated blood components intended for transfusion. Cerus offers INTERCEPT Blood Systems for various components of donated blood, including platelets, plasma, red blood cells, and cryoprecipitated fibrinogen complex. The company sells its platelet and plasma systems through a combination of direct sales and distributors across multiple regions, including the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Founded in 1991 and headquartered in Concord, California, Cerus Corporation is dedicated to providing safe and effective blood products to patients worldwide.
Cerus's ticker is CERS
The company's shares trade on the NASDAQ stock exchange
They are based in Concord, California
There are 201-500 employees working at Cerus
It is cerus.com
Cerus is in the Healthcare sector
Cerus is in the Biotechnology industry
The following five companies are Cerus's industry peers: